Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The.
Speaker 2: Stock Movers Report, your roundup of companies making moves in
Speaker 2: the stock market, harnessing the power of Bloomberg Data.
Speaker 1: Let's take a look at some of the stocks on
Speaker 1: the move today on Paul Swenya alongside Alexis Christopherus and
Speaker 1: we're joined by Bloomberg's Christina. You know, Christine, what are
Speaker 1: you looking at today? Well, well, let's talk about in
Speaker 1: Video because that is the one stock that is on
Speaker 1: everybody's minds this morning. So ticker NVDA. Those shares are
Speaker 1: down more than two percent, two and a half percent
Speaker 1: at the moment, actually, and that is because we did
Speaker 1: get that reporting from the Financial Times saying that China's
Speaker 1: Internet regulator has told the country's biggest technology companies to
Speaker 1: stop buying in Vidia chips, specifically the rtx pro six
Speaker 1: thousand D chips. Now, this chip isn't regarded as among
Speaker 1: in Vidia's marquee products. It's more of a high end card.
Speaker 1: They designed it specifically for the restricted Chinese market. But
Speaker 1: now we have this order from the Chinese authorities telling
Speaker 1: their biggest companies to not buy the jit We did
Speaker 1: get a report from the BBC quoting and Viga CEO
Speaker 1: Jensen Huang saying that he's quote disappointed by the ruling
Speaker 1: and that he would be quote patients in responding to
Speaker 1: it right. Also, Christine, General Mills, I guess benefiting from
Speaker 1: the fact that more folks are eating at home, they're
Speaker 1: eating out less.
Speaker 2: But I'm looking at the stock, it's not doing much
Speaker 2: of anything right now.
Speaker 1: Yeah, absolutely, Alexi sits down, So ticker gis General Mills
Speaker 1: shares down just a tenth of one percent at the moment.
Speaker 1: So clearly the first quarter adjusted EPs beat not doing
Speaker 1: much to lift that stock at the moment, but they
Speaker 1: did get that beat. It's eighty six cents topping analyst estimates.
Speaker 1: In the company was saying that is indeed the rise
Speaker 1: of home cooking among value conscious consumers that are struggling
Speaker 1: with inflation. That has helped some of their segments, including
Speaker 1: rice and beans. But at the same time, there is
Speaker 1: kind of a warning in there. They did say that
Speaker 1: sales in North America retail segment dropped thirteen percent for
Speaker 1: the quarter to two point six billion, So that's probably
Speaker 1: people substituting in store brands for name brands.
Speaker 2: I know, I am I know, I am and I
Speaker 2: am all of that the last four or five years.
Speaker 1: Yeah, So that's probably why we're not getting much of
Speaker 1: a lift because there is it's a bit of a
Speaker 1: double edged sword kind of report from General Mills today.
Speaker 1: You spend generations building up brand value and then puff gone.
Speaker 1: That's what a little inflation will take. That's what a
Speaker 1: little inflation to do. L l y Eli Lilly, l
Speaker 1: y Eli Lilly. So those shares not up by much,
Speaker 1: just about to four tens of one percent at the moment.
Speaker 1: But they did get good news from a trial of
Speaker 1: their golp one drug. It's an oral drug, experimental diabetes pill,
Speaker 1: which showed that people on this for the trial lost
Speaker 1: more weight and had a better blood sugar control than
Speaker 1: those in an older approved rival from Novo Nordisk. So
Speaker 1: this is a head to it drug trial. Patients that
Speaker 1: were given Eli Lilly's oral drug lost eight point two
Speaker 1: percent of their body weight in fifty two weeks versus
Speaker 1: five point three percent for the Novo drug. So doctors
Speaker 1: who were kind of they presented the results of doctors
Speaker 1: and the doctors saying that the results look positive. They
Speaker 1: say that the tablet will make it possible to treat
Speaker 1: more patients because it's easier to produce and to take
Speaker 1: given that it is an oral drug.
Speaker 2: The Stock Mover's report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 2: the Bloomberg Business app.